Diamyd Medical updates U.S. market potential for Diamyd®
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum) in the U.S. market. The addressable patient population for its launch indication is estimated at over 60,000 individual patients, with annual peak sales projections well exceeding block buster potential(*). Diamyd® has Orphan Drug Designation status in the U.S. for its launch indication, and follow-on indications represent a market potential that is expected to equal or even exceed its primary indication.
*Defined as annual sales of at least $1 billion.
Addressable market at launch
The addressable market for Diamyd® at launch consists of two distinct populations, both comprising patients aged 12 years and older.
1. Newly diagnosed Stage 3 Type 1 Diabetes patientsIn 2024, approximately
47,000 patients in the U.S. are expected to be newly diagnosed with Stage
3 T1D. Of these, an estimated 19,000 individuals (40 %) are HLA DR3-DQ2
positive and eligible for Diamyd® treatment.
2. Recently diagnosed Type 1 Diabetes patients with retained beta cell
functionAn additional opportunity exists among recently diagnosed Type 1
Diabetes patients who retain beta cell function for up to two years
following diagnosis. This population is estimated at 62,000 individuals
in 2024, of whom approximately 25,000 are HLA positive. While this group
is expected to shrink as Diamyd® is adopted in newly diagnosed patients,
it will remain a significant contributor to the addressable market.
These combined populations will annually total over 60,000 patients in the U.S. the coming years when accounting for incidence and population growth.
Market assumptions
-- Pricing: Diamyd®'s base case gross price is projected at $157,000 per
course, supported by market research with payers and providers. Limited
standard Gross-to-Net discounts, which account for rebates, discounts,
and other payer incentives, are expected. The final gross price will be
dependent on the Phase 3 data, with potential for a gross price up to
$200,000 per course. Price increases of 2% per year are expected.
-- Access and coverage: Diamyd® is expected to achieve over 80 % market
access. This is based on broad insurance coverage of Type 1 Diabetes and
expected high prior authorization approvals, reflecting its strong
clinical differentiation as a disease-modifying therapy and its status
having an FDA granted orphan drug designation.
-- Market penetration: Qualitative market research supports an estimate of
at least 30 % of Type 1 Diabetes patients being a reasonable penetration
assumption for base case projections.
Clear growth drivers and upsides
-- Latent Autoimmune Diabetes in Adults (LADA): LADA, a condition affecting
approximately 7 % of the 1.2 million adults diagnosed annually with Type
2 Diabetes in the U.S., represents an addressable market that is equal
or larger than the Stage 3 Type 1 Diabetes market.
-- Earlier Type 1 Diabetes Stages: Expanding Diamyd®'s indication to
include Stage 1 and Stage 2 Type 1 Diabetes patients offers
opportunities for early intervention. The size of the addressable market
is heavily dependent on the availability and coverage of screening
programs.
-- Booster courses: Booster treatments for patients previously treated with
Diamyd® present an additional market segment.
-- Ex-U.S. market: Global opportunities could account for an additional 40
% of Diamyd®'s total sales potential, based on analogs from the Type 2
Diabetes market.
The market research underscores the importance of enhancing Health Care Practitioner (HCP) education and engagement, as many physicians lack familiarity with the genetic and clinical profiling necessary to identify eligible patients, such as HLA testing and C-peptide measurements. Given that Diamyd® could be the first or among the first therapies approved to preserve insulin-producing capacity in Type 1 Diabetes, measured by C-peptide, it is essential to educate HCPs, patient advocacy groups, and payers about the critical value of maintaining endogenous insulin production and its long-term benefits for patient outcomes.
The market research was conducted in collaboration with the Kondrad Consulting Group, LLC, Sarasota, FL USA, www.kondradconsulting.com.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Breakthrough Designation and Fast Track Designation by the U.S. FDA for the treatment of Stage 3 Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company's prospective European Phase IIb trial, where Diamyd® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymph node can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umea, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.
Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
https://mb.cision.com/Main/6746/4090306/3201329.pdf PDF version
View original content:https://www.prnewswire.com/news-releases/diamyd-medical-updates-us-market-potential-for-diamyd-302349062.html
SOURCE Diamyd Medical AB
